284 related articles for article (PubMed ID: 17118412)
21. Lipopolysaccharide dose dependently impairs rapid toxin (LiCl)-induced gustatory conditioning: a taste reactivity examination of the conditioned taste aversion.
Cross-Mellor SK; Foley KA; Parker LA; Ossenkopp KP
Brain Behav Immun; 2009 Feb; 23(2):204-16. PubMed ID: 18835436
[TBL] [Abstract][Full Text] [Related]
22. Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys.
Nakamura-Palacios EM; Winsauer PJ; Moerschbaecher JM
Behav Pharmacol; 2000 Aug; 11(5):377-86. PubMed ID: 11103889
[TBL] [Abstract][Full Text] [Related]
23. The effect of Delta9-tetrahydrocannabinol on sensorimotor gating in socially isolated rats.
Malone DT; Taylor DA
Behav Brain Res; 2006 Jan; 166(1):101-9. PubMed ID: 16143410
[TBL] [Abstract][Full Text] [Related]
24. Morphine enhancement of sucrose palatability: analysis by the taste reactivity test.
Rideout HJ; Parker LA
Pharmacol Biochem Behav; 1996 Mar; 53(3):731-4. PubMed ID: 8866978
[TBL] [Abstract][Full Text] [Related]
25. Naltrexone modifies the palatability of basic tastes and alcohol in outbred male rats.
Ferraro FM; Hill KG; Kaczmarek HJ; Coonfield DL; Kiefer SW
Alcohol; 2002 Jun; 27(2):107-14. PubMed ID: 12106830
[TBL] [Abstract][Full Text] [Related]
26. A comparison of the effects of the CB(1) receptor antagonist SR141716A, pre-feeding and changed palatability on the microstructure of ingestive behaviour.
Thornton-Jones ZD; Kennett GA; Vickers SP; Clifton PG
Psychopharmacology (Berl); 2007 Jul; 193(1):1-9. PubMed ID: 17372721
[TBL] [Abstract][Full Text] [Related]
27. The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding.
Boctor SY; Martinez JL; Koek W; France CP
Eur J Pharmacol; 2007 Sep; 571(1):39-43. PubMed ID: 17628534
[TBL] [Abstract][Full Text] [Related]
28. Effects of SR141716A on diazepam substitution for delta9-tetrahydrocannabinol in rat drug discrimination.
Wiley JL; Martin BR
Pharmacol Biochem Behav; 1999 Nov; 64(3):519-22. PubMed ID: 10548265
[TBL] [Abstract][Full Text] [Related]
29. Delta9-tetrahydrocannabinol-induced conditioned place preference and intracerebroventricular self-administration in rats.
Braida D; Iosuè S; Pegorini S; Sala M
Eur J Pharmacol; 2004 Dec; 506(1):63-9. PubMed ID: 15588625
[TBL] [Abstract][Full Text] [Related]
30. Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice.
Riedel G; Fadda P; McKillop-Smith S; Pertwee RG; Platt B; Robinson L
Br J Pharmacol; 2009 Apr; 156(7):1154-66. PubMed ID: 19378378
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats.
Carta G; Nava F; Gessa GL
Brain Res; 1998 Oct; 809(1):1-4. PubMed ID: 9795096
[TBL] [Abstract][Full Text] [Related]
32. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
[TBL] [Abstract][Full Text] [Related]
33. Delta9-tetrahydrocannbinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice.
Varvel SA; Bridgen DT; Tao Q; Thomas BF; Martin BR; Lichtman AH
J Pharmacol Exp Ther; 2005 Jul; 314(1):329-37. PubMed ID: 15831444
[TBL] [Abstract][Full Text] [Related]
34. Endocannabinoid hedonic hotspot for sensory pleasure: anandamide in nucleus accumbens shell enhances 'liking' of a sweet reward.
Mahler SV; Smith KS; Berridge KC
Neuropsychopharmacology; 2007 Nov; 32(11):2267-78. PubMed ID: 17406653
[TBL] [Abstract][Full Text] [Related]
35. Two distinctive antinociceptive systems in rats with pathological pain.
Mao J; Price DD; Lu J; Keniston L; Mayer DJ
Neurosci Lett; 2000 Feb; 280(1):13-6. PubMed ID: 10696800
[TBL] [Abstract][Full Text] [Related]
36. Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits Δ9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.
Klumpers LE; Roy C; Ferron G; Turpault S; Poitiers F; Pinquier JL; van Hasselt JG; Zuurman L; Erwich FA; van Gerven JM
Br J Clin Pharmacol; 2013 Jul; 76(1):65-77. PubMed ID: 23278647
[TBL] [Abstract][Full Text] [Related]
37. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems.
Solinas M; Goldberg SR
Neuropsychopharmacology; 2005 Nov; 30(11):2035-45. PubMed ID: 15812567
[TBL] [Abstract][Full Text] [Related]
38. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
39. The role of the ventral pallidum GABAergic system in conditioned taste aversion: effects of microinjections of a GABAA receptor antagonist on taste palatability of a conditioned stimulus.
Inui T; Shimura T; Yamamoto T
Brain Res; 2007 Aug; 1164():117-24. PubMed ID: 17640625
[TBL] [Abstract][Full Text] [Related]
40. The in vitro and in vivo cardiovascular effects of Delta9-tetrahydrocannabinol in rats made hypertensive by chronic inhibition of nitric-oxide synthase.
O'Sullivan SE; Randall MD; Gardiner SM
J Pharmacol Exp Ther; 2007 May; 321(2):663-72. PubMed ID: 17284670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
